To address the misconceptions and risks associated with microdosing GLP-1 medications for weight loss.
Key Findings:
Microdosing GLP-1s is not supported by legitimate long-term data.
FDA-approved doses are the only ones studied for safety and efficacy.
Compounded products marketed for microdosing are not FDA-approved and lack rigorous clinical studies.
There is a risk of contamination when using single-use vials multiple times.
Interpretation:
Microdosing GLP-1 medications for weight loss is not a medically recognized practice and poses significant risks due to lack of regulation and research.
Limitations:
No long-term data on the safety and efficacy of microdosing.
Lack of standardized definitions and practices regarding microdosing.
Conclusion:
While microdosing is popularized, it is fraught with risks and lacks scientific backing; further research is needed to explore the potential of GLP-1 therapies.
